It will be very interesting to further investigate on these molecular mechanisms, since the knowledge of this matter will support the application of NT5C2 inhibitors not only in cancer but also in pathologies such as metabolic syndrome, obesity and diabetes. This evidence concerns the gene NT5C2 and cancer.